Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Method of Treating or Preventing Oxidative Stress-related Diseases (stroke and neurodegenerative diseases, wound healing and car

Posted Jun 30 2007 5:00pm

Description of Invention:
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) produce oxidative stress to DNA, lipids and proteins thus causing cellular and tissue damage. A number of diseases are associated with oxidative stress including Alzheimer's disease, ischemic stroke, heart disease, cancer, hepatitis, and autoimmune disease. Uric acid is a natural antioxidant effective in reducing ROS and research has shown that uric acid contributes approximately two-thirds of all free radical scavenging capacity in plasma. Because uric oxide is too insoluble to be used as a therapeutic agent, scientists at the NIH developed uric acid analogs with improved anti-oxidative and solubility properties for use as free radical scavengers or antioxidants. These analogs increased survival of PC12 and hippocampal neurons after challenge by Fe, MPP and Glutamate. When administered to a mouse model of focal ischemic stroke, these compounds protect neuronal cells from ROS and reduce brain damage and ameliorate neurological deficits. Other studies show a single application of these analogs on skin lacerations in mice decreased the time for wound repair. Available for licensing are methods of treating ischemic stroke and wound healing, and for the prevention or treatment of other oxidative stress-related diseases, such as epilepsy, Parkinson's disease and dementia.

Applications:
Novel uric acid analogs for use as antioxidants to help reduce the risk of stroke, neurological diseases and assisting with wound repair.

Development Status:
Pre-clinical data.

Inventors:
Nigel H Greig (NIA)
Mark P Mattson (NIA)


Patent Status:
HHS, Reference No. E-059-2006/0
US, Application No. 12/377,881 filed 18 Feb 2009


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute on Aging, Laboratory of Neurosciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the described uric acid analogue technology in the treatment of neurodegenerative diseases, wound healing and cardiovascular disease. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Central Nervous System
Central Nervous System - Therapeutics



For Additional Information Please Contact:
Norbert Pontzer Ph.D., J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 23,
Rockville, MD 20852
United States
Email: pontzern@mail.nih.gov
Phone: 301-435-5502
Fax: 301-402-0220


Ref No: 1577

Updated: 07/2007

Post a comment
Write a comment:

Related Searches